Proellex� Administered As Cyclic Therapy For Uterine Fibroids Symptoms For Up To 30 Months Shows No Adverse Effects On The Endometrium Repros Therapeutics Inc. (NasdaqGM:RPRX) today released strong results from its completed extension safety study of Proellex in the chronic treatment of the symptoms associated with uterine fibroids. To date there have been no abnormal histological findings from the endometrial biopsies taken post menses after cessation of drug administration.
Source: www.medicalnewstoday.com
# posted by Network @ 7:00 AM
